Glycosylation News and Research

RSS

A cost-effective scalable production of SARS-CoV-2 RBD in yeast

A new study by the Argentinian AntiCovid Consortium and published in the preprint server bioRxiv* in September 2020 reports on the successful characterization of the conformation and stability of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in two different cell systems. This may help to accelerate the development of vaccines and neutralizing antibodies.

21 Sep 2020

Research identifies new alteration in the brain of people with Alzheimer's

Despite the important advances in research in recent years, the etiopathogenesis of Alzheimer's disease is still not fully clarified. One of the key questions is to decipher why the production of beta amyloid, the protein that produces the toxic effect and triggers the pathology, increases in the brain of people with Alzheimer's.

19 Sep 2020

Study highlights role of specific protein in the mass production of antibodies

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic.

16 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated

However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a valuable step in using it for these purposes.

30 Aug 2020

The Native Antigen Company announces custom contract service to develop influenza A and B antigens

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of its custom contract service to rapidly develop antigen panels for influenza A and B viruses.

21 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

Can SARS-CoV-2 be transmitted via feces?

A new study by researchers at the University of Oxford and the Trip Medical Database and published on the preprint server medRxiv* in August 2020 as part of the ongoing Open Evidence Review on Transmission Dynamics of COVID-19 reports the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in feces and the need for precautions to prevent orofecal spread in the surroundings of confirmed or suspected cases.

12 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Scientists find new way of identifying and targeting hidden HIV viral reservoirs during ART therapy

Scientists at The Wistar Institute may have discovered a new way of identifying and targeting hidden HIV viral reservoirs during treatment with antiretroviral therapy (ART).

7 Aug 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

War of sugars - estrogen provides protection in COVID-19

Now a new study published on the preprint server bioRxiv in July 2020 reports that sex hormones could affect the function of the fusion protein that is dependent upon the human ACE2 receptor, thus preventing the entry of the virus into the host cell.

31 Jul 2020

Study finds synthetic neutralizing/enhancing antibodies to SARS-CoV-2

A new study published on the preprint server bioRxiv in July 2020 reports the discovery of some antibody molecules that have powerful enhancing or neutralizing activity against the virus, in a library of synthetic antibodies. These hold the promise of being useful for the prevention or treatment of this illness.

30 Jul 2020

Glycome shift in epidermal stem cells could serve as potential biomarker of aging

Age shows nowhere better than on the skin. The ravages of time on skin and the epidermal stem cells that differentiate to replenish its outer layer have been hypothesized, but there has been no method to evaluate their aging at the molecular level.

21 Jul 2020

Certain antibodies may cause the dangerous part of COVID-19 disease

A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.

15 Jul 2020

Study of glycosylation on SARS-CoV-2 spike protein

The first intimation of the current COVID-19 crisis came with the news of severe pneumonic illness caused by an unknown agent in a Chinese city called Wuhan, issued on the last day of 2019. Following this, researchers found the cause to be a novel coronavirus, closely related to the earlier SARS virus, now called severe acute respiratory syndrome coronavirus 2.

8 Jul 2020

Spike proteins of SARS-CoV-2 covered by mobile glycans that shield its surface

A new study of the structural dynamics of the SARS-CoV-2 spike protein published in the preprint server bioRxiv in July 2020 reports on the epitopes that could be possible immune targets for the development of vaccines.

7 Jul 2020

Striking CryoEM image of SARS-CoV-2

A new study by researchers from the UK and Germany and published on the preprint server bioRxiv in June 2020 reports the results of a detailed study of the S protein on the intact virus, using cryoelectron microscopy (cryoEM) and tomography. This could help understand the conformation of the S protein on the virion and how it interacts with neutralizing antibodies.

30 Jun 2020

Research shows how a protein's small change leads to big trouble for cells

In molecular biology, chaperones are a class of proteins that help regulate how other proteins fold. Folding is an important step in the manufacturing process for proteins. When they don't fold the way they're supposed to, it can lead to the development of diseases such as cancer.

30 Jun 2020